Randomized, Double-Blind Study of Stibogluconate Plus Human Granulocyte Macrophage Colony-Stimulating Factor versus Stibogluconate Alone in the Treatment of Cutaneous Leishmaniasis
Almeida R, D'Oliveira A, Machado P, Bacellar O, Ko A, de Jesus A, Mobashery N, Santos J, Carvalho E. Randomized, Double-Blind Study of Stibogluconate Plus Human Granulocyte Macrophage Colony-Stimulating Factor versus Stibogluconate Alone in the Treatment of Cutaneous Leishmaniasis. The Journal Of Infectious Diseases 1999, 180: 1735-1737. PMID: 10515844, DOI: 10.1086/315082.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntimony Sodium GluconateAntiprotozoal AgentsChildDouble-Blind MethodDrug Therapy, CombinationFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansLeishmaniasis, CutaneousMaleMiddle AgedConceptsCutaneous leishmaniasisGM-CSFDouble-blind placebo trialDouble-blind studyRecombinant human granulocyte-macrophage colony-stimulating factorGranulocyte macrophage-colony stimulating factorGM-CSF groupGranulocyte-macrophage colony-stimulating factorMacrophage-colony stimulating factorMacrophage colony-stimulating factorColony-stimulating factorHuman granulocyte macrophage-colony stimulating factorHuman granulocyte-macrophage colony-stimulating factorPlacebo groupPlacebo trialLesion healingSodium stibogluconatePatientsStibogluconateLeishmaniasisLesionsDaysTreatmentPlaceboGroup